KIT RS3733542

CI-VAR-00003947Explore in graph →NP_000213.1:p.Leu862=NM_000222.2:c.2586G>CClinVar 255572 CIViC 482 rs3733542

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia1
KIT RS3733542	Selumetinib	Predictive	B	Supports Sensitivity Response	1	accepted	EID1136 Patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study of selumetinib and analyzed for mutations in KIT, NRAS, KRAS and FLT3. KIT mutation a… (full text at CIViC) PMID 24178622 · Jain et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
255572	Benign/Likely benign	criteria provided, multiple submitters, no conflicts	2	Piebaldism; Gastrointestinal stromal tumor; Mastocytosis; Hereditary cancer-predisposing syndrome	germline	10	Jun 05, 2026	clinvar